33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A new role for the SRC family member HCK as a driver of BCR/SYK signaling in MYD88 mutated lymphomas
    Meeting Abstract

    Munshi, M.; Liu, X.; Kofides, A.; Tsakmaklis, N.; Demos, M. G.; Guerrera, M. L.; Hunter, Z. R.; Palomba, M. L.; Argyropoulos, K. V.; Patterson, C. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Graded cardiac response criteria for AL amyloidosis: The impact of depth of cardiac response on survival
    Meeting Abstract

    Muchtar, E.; Dispenzieri, A.; Wisniowski, B.; Palladini, G.; Milani, P.; Merlini, G.; Schönland, S.; Veelken, K.; Hegenbart, U.; Kumar, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Graded renal response criteria for light chain (AL) amyloidosis
    Meeting Abstract

    Muchtar, E.; Wisniowski, B.; Palladini, G.; Milani, P.; Merlini, G.; Schönland, S.; Veelken, K.; Hegenbart, U.; Dispenzieri, A.; Kumar, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT)
    Meeting Abstract

    Mishra, A.; Tamari, R.; DeZern, A. E.; Byrne, M. T.; Gooptu, M.; Chen, Y. B.; Deeg, H. J.; Gallacher, P.; Wennborg, A.; Hickman, D. K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Acute leukemia and COVID-19: The Johns Hopkins experience
    Meeting Abstract

    Miller, K. P.; Brown, P. A.; Smith, B. D.; Webster, J.; Powell, H.; Duffield, A. S.
    Blood (2021)

    Fulltext@MSK | Save
  • Six-year results from the phase 3 randomized study relevance show similar outcomes for previously untreated follicular lymphoma patients receiving lenalidomide plus rituximab (R (2)) versus rituximab-chemotherapy followed by rituximab maintenance
    Meeting Abstract

    Morschhauser, F.; Nastoupil, L.; Feugier, P.; De Colella, J. M. S.; Tilly, H.; Palomba, M. L.; Bachy, E.; Fruchart, C.; Libby, E.; Casasnovas, R. O.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • BTG1 mutation promotes aggressive lymphoma development by lowering the threshold to MYC activation and generating "super-competitor" B cells
    Meeting Abstract

    Mlynarczyk, C.; Teater, M.; Pae, J.; Arulraj, T.; Chin, C. R.; Wang, L.; Ersching, J.; Kots, E.; Chadburn, A.; Barin, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Efficacy and safety results from ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: Update after 48 weeks
    Meeting Abstract

    Mauro, M. J.; Minami, Y.; Rea, D.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A. G.; Kim, D. W.; Apperley, J. F.; Cortes, J. E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • End of treatment peripheral blood TCR evaluation for minimal residual disease evaluation in peripheral T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Jacobsen, E. D.; Fehniger, T. A.; Kahl, B. S.; Bartlett, N. L.; Cashen, A. F.; Ghobadi, A.; Reagan, B.; Fischer, A.; Moskowitz, A. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Post-transplant inotuzumab ozogamicin for acute lymphoblastic leukemia
    Meeting Abstract

    Metheny, L. 3rd; Sobecks, R. M.; Cho, C.; Caimi, P. F.; Majhail, N. S.; Otegbeye, F.; Boughan, K. M.; Cooper, B. W.; Galloway, E.; Gallogly, M.; more...
    Blood (2021)

    Fulltext@MSK | Save